Positive phase III results for baloxavir marboxil in people at high risk of complications from influenza to be presented at IDWeek 2018

Roche today announced that the phase III CAPSTONE-2 study showed treatment with baloxavir marboxil significantly reduced the time to improvement of influenza symptoms versus placebo (median time of 73.2 hours versus 102.3 hours; p
Source: Roche Media News - Category: Pharmaceuticals Source Type: news